Siqi Hu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Siqi Hu has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Ji-Young Lee
University of Connecticut
8 shared publications Minkyung Bae
Department of Nutritional Sciences, University of Connecticut, Storrs, CT 06269, USA
4 shared publicationsTho X. Pham
Department of Nutritional Sciences, University of Connecticut, Storrs, CT, USA
4 shared publicationsYoojin Lee
Department of Nutritional Sciences, University of Connecticut, Storrs, CT 06269, USA
4 shared publicationsYoung-Ki Park
Department of Nutritional Sciences, University of Connecticut, Storrs, CT 06269, USA
4 shared publicationsHyunju Kang
Department of Nutritional Sciences, University of Connecticut, Storrs, CT 06269, USA
3 shared publications
Latest Publications
- Open Access
A Real World Dataset for Multi-view 3D Reconstruction
We present a dataset of 998 3D models of everyday tabletop objects along with their 847,000 real world RGB and depth images. Accurate annotations of camera poses and object poses for each image are performed in a semi-automated fashion to facilitate the use of the dataset for myriad 3D applications like shape reconstruction, object pose estimation, shape retrieval etc. We primarily focus on learned multi-view 3D reconstruction due to the lack of appropriate real world benchmark for the task and demonstrate that our dataset can fill that gap. The entire annotated dataset along with the source code for the annotation tools and evaluation baselines is available at http://www.ocrtoc.org/3d-reconstruction.html.
Open AccessA Real World Dataset for Multi-view 3D Reconstruction
We present a dataset of 998 3D models of everyday tabletop objects along with their 847,000 real world RGB and depth images. Accurate annotations of camera poses and object poses for each image are performed in a semi-automated fashion to facilitate the use of the dataset for myriad 3D applications like shape reconstruction, object pose estimation, shape retrieval etc. We primarily focus on learned multi-view 3D reconstruction due to the lack of appropriate real world benchmark for the task and demonstrate that our dataset can fill that gap. The entire annotated dataset along with the source code for the annotation tools and evaluation baselines is available at http://www.ocrtoc.org/3d-reconstruction.html.
- Open Access
- 30 June 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (2) , 1801-1812
Mental health disorders among ovarian cancer survivors in a population‐based cohort
Background: Ovarian cancer is the fifth most common female cancer in the United States. There have been very few studies investigating mental health diagnoses among ovarian cancer survivors with long‐term follow up. The aim of this study is to examine the incidence of mental illness among ovarian cancer survivors compared to a general population cohort. A secondary aim is to investigate risk factors for mental illnesses among ovarian cancer survivors.Patients and methods: Cohorts of 1689 ovarian cancer patients diagnosed between 1996 and 2012 and 7038 women without cancer matched by age and birth state from the general population were identified. Mental health diagnoses were identified from electronic medical records and statewide healthcare facilities data. Cox proportional hazard models were used to estimate hazard ratios (HRs).Results: Ovarian cancer survivors experienced increased risks of mental illnesses within the first 2 years after cancer diagnosis (HR = 3.55, 95% CI = 3.04–4.14). The risks of depression among ovarian cancer survivors were nearly 3‐fold within the first 2 years of cancer diagnosis (HR = 2.59, 95% CI = 1.94–3.47), and 1.69‐fold at 2–5 years after cancer diagnosis (HR = 1.69, 95% CI = 1.18–2.42). Ovarian cancer survivors experienced an 80% increased risk of death with a mental illness diagnosis (HR = 1.80, 95% CI = 1.48–2.18) and a 94% increased risk of death with a depression diagnosis (HR = 1.94, 95% CI = 1.56–2.40).Conclusions: Higher risks of mental illnesses were observed among ovarian cancer survivors throughout the follow‐up periods of 0–2 years and 2–5 years after cancer diagnosis. Multidisciplinary care is needed to monitor and treat mental illnesses among ovarian cancer survivors.
- 30 June 2022
- Published by Wiley in Cancer Medicine
- Vol. 12 (2) , 1801-1812
Open AccessMental health disorders among ovarian cancer survivors in a population‐based cohort
Background: Ovarian cancer is the fifth most common female cancer in the United States. There have been very few studies investigating mental health diagnoses among ovarian cancer survivors with long‐term follow up. The aim of this study is to examine the incidence of mental illness among ovarian cancer survivors compared to a general population cohort. A secondary aim is to investigate risk factors for mental illnesses among ovarian cancer survivors.Patients and methods: Cohorts of 1689 ovarian cancer patients diagnosed between 1996 and 2012 and 7038 women without cancer matched by age and birth state from the general population were identified. Mental health diagnoses were identified from electronic medical records and statewide healthcare facilities data. Cox proportional hazard models were used to estimate hazard ratios (HRs).Results: Ovarian cancer survivors experienced increased risks of mental illnesses within the first 2 years after cancer diagnosis (HR = 3.55, 95% CI = 3.04–4.14). The risks of depression among ovarian cancer survivors were nearly 3‐fold within the first 2 years of cancer diagnosis (HR = 2.59, 95% CI = 1.94–3.47), and 1.69‐fold at 2–5 years after cancer diagnosis (HR = 1.69, 95% CI = 1.18–2.42). Ovarian cancer survivors experienced an 80% increased risk of death with a mental illness diagnosis (HR = 1.80, 95% CI = 1.48–2.18) and a 94% increased risk of death with a depression diagnosis (HR = 1.94, 95% CI = 1.56–2.40).Conclusions: Higher risks of mental illnesses were observed among ovarian cancer survivors throughout the follow‐up periods of 0–2 years and 2–5 years after cancer diagnosis. Multidisciplinary care is needed to monitor and treat mental illnesses among ovarian cancer survivors.
- Open Access
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3657
Abstract 3657: Mental health disorders among prostate cancer patients in a population-based cohort
Background. Prostate cancer is the most common malignancy among men in the United States. Few studies evaluate mental health disorders comprehensively among prostate cancer patients with long-term follow-up. The primary aim of our study is to assess the incidence of mental health disorders among prostate cancer patients compared to a general population cohort. A secondary aim is to investigate risk factors for mental health disorders among prostate cancer patients. Methods. Cohorts of 18,134 cancer patients with prostate adenocarcinomas diagnosed between 2004 and 2017 and 73,470 men without cancer matched by age, birth state and follow up time from the general population were identified. Mental health diagnoses were identified from electronic medical records and statewide healthcare facilities data. Cox proportional hazard models were used to estimate hazard ratios (HRs). Results. Prostate cancer patients had increased risks of mental illnesses for the first five years after cancer diagnosis (0-2 years: HR=1.81, 95%CI=1.75-1.87; 2-5 years: HR=1.05, 95%CI=1.01-1.08) compared to the general population, but not in the later follow up periods. Elevated risks of anxiety disorder among prostate cancer patients were observed during across follow-up periods (0-2 years: HR= 1.59, 95% CI= 1.49-1.70; 2-5 years: HR= 1.20, 95% CI= 1.12-1.28; 5-10 years: HR= 1.20, 95% CI= 1.12-1.29; 10- 16 years: HR= 1.29, 95% CI= 1.14-1.45). Likewise, mood disorders, including depressive disorders, among prostate cancer survivors were found for all follow-up periods (0-2 years: HR= 1.59, 95% CI= 1.50-1.69; 2-5 years: HR= 1.21, 95% CI= 1.14-1.29; 5-10 years: HR= 1.20, 95% CI= 1.13-1.28; 10-16 years: HR=1.25, 95% CI= 1.12-1.38).The risks of any mental illness were increased with PSA>20ng/ml, high Gleason score, high-level risk group (intermediate, high, and very high), higher AJCC staging, and androgen deprivation treatment (ADT) therapy within 10 years after prostate cancer diagnosis. Surgery, radiation, ADT and tumor characteristics were also important risk factors for depression at 0-2 years after prostate cancer diagnosis. A baseline Charlson Comorbidity Index score of 1+ and unmarried status were associated with increased risk of any mental illness and depression across all time periods. We also observed that increased risks of any mental illness were associated with Hispanic, black or multiple races, underweight or obese, and family history of prostate cancer for all time periods. Prostate cancer survivors had a 26% increased risk of death associated with a mental illness diagnosis and a 61% increased risk of death with a depression diagnosis. Conclusion. Prostate cancer diagnosis is associated with poor mental health, which was observed as long as 16 years after cancer diagnosis. Providing long-term mental health support may be potentially beneficial to increasing life expectancy for prostate cancer patients. Citation Format: Siqi Hu. Mental health disorders among prostate cancer patients in a population-based cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3657.
- 15 June 2022
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 82 (12_Supplem) , 3657
Open AccessAbstract 3657: Mental health disorders among prostate cancer patients in a population-based cohort
Background. Prostate cancer is the most common malignancy among men in the United States. Few studies evaluate mental health disorders comprehensively among prostate cancer patients with long-term follow-up. The primary aim of our study is to assess the incidence of mental health disorders among prostate cancer patients compared to a general population cohort. A secondary aim is to investigate risk factors for mental health disorders among prostate cancer patients. Methods. Cohorts of 18,134 cancer patients with prostate adenocarcinomas diagnosed between 2004 and 2017 and 73,470 men without cancer matched by age, birth state and follow up time from the general population were identified. Mental health diagnoses were identified from electronic medical records and statewide healthcare facilities data. Cox proportional hazard models were used to estimate hazard ratios (HRs). Results. Prostate cancer patients had increased risks of mental illnesses for the first five years after cancer diagnosis (0-2 years: HR=1.81, 95%CI=1.75-1.87; 2-5 years: HR=1.05, 95%CI=1.01-1.08) compared to the general population, but not in the later follow up periods. Elevated risks of anxiety disorder among prostate cancer patients were observed during across follow-up periods (0-2 years: HR= 1.59, 95% CI= 1.49-1.70; 2-5 years: HR= 1.20, 95% CI= 1.12-1.28; 5-10 years: HR= 1.20, 95% CI= 1.12-1.29; 10- 16 years: HR= 1.29, 95% CI= 1.14-1.45). Likewise, mood disorders, including depressive disorders, among prostate cancer survivors were found for all follow-up periods (0-2 years: HR= 1.59, 95% CI= 1.50-1.69; 2-5 years: HR= 1.21, 95% CI= 1.14-1.29; 5-10 years: HR= 1.20, 95% CI= 1.13-1.28; 10-16 years: HR=1.25, 95% CI= 1.12-1.38).The risks of any mental illness were increased with PSA>20ng/ml, high Gleason score, high-level risk group (intermediate, high, and very high), higher AJCC staging, and androgen deprivation treatment (ADT) therapy within 10 years after prostate cancer diagnosis. Surgery, radiation, ADT and tumor characteristics were also important risk factors for depression at 0-2 years after prostate cancer diagnosis. A baseline Charlson Comorbidity Index score of 1+ and unmarried status were associated with increased risk of any mental illness and depression across all time periods. We also observed that increased risks of any mental illness were associated with Hispanic, black or multiple races, underweight or obese, and family history of prostate cancer for all time periods. Prostate cancer survivors had a 26% increased risk of death associated with a mental illness diagnosis and a 61% increased risk of death with a depression diagnosis. Conclusion. Prostate cancer diagnosis is associated with poor mental health, which was observed as long as 16 years after cancer diagnosis. Providing long-term mental health support may be potentially beneficial to increasing life expectancy for prostate cancer patients. Citation Format: Siqi Hu. Mental health disorders among prostate cancer patients in a population-based cohort [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3657.
- Open Access
Consumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
Fucoxanthin (FCX) is a xanthophyll carotenoid present in brown seaweed. The goal of this study was to examine whether FCX supplementation could attenuate obesity-associated metabolic abnormalities, fibrosis, and inflammation in two diet-induced obesity (DIO) mouse models. C57BL/6J mice were fed either a high-fat/high-sucrose/high-cholesterol (HFC) diet or a high-fat/high-sucrose (HFS) diet. The former induces more severe liver injury than the latter model. In the first study, male C57BL/6J mice were fed an HFC diet, or an HFC diet containing 0.015% or 0.03% (w/w) FCX powder for 12 weeks to develop obesity-induced nonalcoholic steatohepatitis (NASH). In the second study, mice were fed an HFS diet or an HFS diet containing 0.01% FCX powder for 8 weeks. FCX did not change body weight gain and serum lipid profiles compared to the HFC or HFS controls. No significant differences were present in liver triglyceride and total cholesterol, hepatic fat accumulation, and serum alanine aminotransferase levels between control and FCX-fed mice regardless of whether they were on an HFC or HFS diet. FCX did not mitigate mRNA abundance of genes involved in lipid synthesis, cholesterol metabolism, inflammation, and fibrosis in the liver and white adipose tissue, while hepatic fatty acid β-oxidation genes were significantly elevated by FCX in both HFC and HFS feeding studies. Additionally, in the soleus muscle, FCX supplementation significantly elevated genes that regulate mitochondrial biogenesis and fatty acid β-oxidation, concomitantly increasing mitochondrial DNA copy number, compared with HFC. In summary, FCX supplementation had minor effects on hepatic and white adipose inflammation and fibrosis in two different DIO mouse models.
Open AccessConsumption of Low Dose Fucoxanthin Does Not Prevent Hepatic and Adipose Inflammation and Fibrosis in Mouse Models of Diet-Induced Obesity
Fucoxanthin (FCX) is a xanthophyll carotenoid present in brown seaweed. The goal of this study was to examine whether FCX supplementation could attenuate obesity-associated metabolic abnormalities, fibrosis, and inflammation in two diet-induced obesity (DIO) mouse models. C57BL/6J mice were fed either a high-fat/high-sucrose/high-cholesterol (HFC) diet or a high-fat/high-sucrose (HFS) diet. The former induces more severe liver injury than the latter model. In the first study, male C57BL/6J mice were fed an HFC diet, or an HFC diet containing 0.015% or 0.03% (w/w) FCX powder for 12 weeks to develop obesity-induced nonalcoholic steatohepatitis (NASH). In the second study, mice were fed an HFS diet or an HFS diet containing 0.01% FCX powder for 8 weeks. FCX did not change body weight gain and serum lipid profiles compared to the HFC or HFS controls. No significant differences were present in liver triglyceride and total cholesterol, hepatic fat accumulation, and serum alanine aminotransferase levels between control and FCX-fed mice regardless of whether they were on an HFC or HFS diet. FCX did not mitigate mRNA abundance of genes involved in lipid synthesis, cholesterol metabolism, inflammation, and fibrosis in the liver and white adipose tissue, while hepatic fatty acid β-oxidation genes were significantly elevated by FCX in both HFC and HFS feeding studies. Additionally, in the soleus muscle, FCX supplementation significantly elevated genes that regulate mitochondrial biogenesis and fatty acid β-oxidation, concomitantly increasing mitochondrial DNA copy number, compared with HFC. In summary, FCX supplementation had minor effects on hepatic and white adipose inflammation and fibrosis in two different DIO mouse models.
- 1 July 2021
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 93, 108636
Erratum to “Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis” [The Journal of Nutritional Biochemistry Volume 85 (2020) 108463]
- 1 July 2021
- Published by Elsevier in The Journal of Nutritional Biochemistry
- Vol. 93, 108636
Erratum to “Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis” [The Journal of Nutritional Biochemistry Volume 85 (2020) 108463]
- Open Access
- 26 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Establishment and application of a novel method based on single nucleotide polymorphism analysis for detecting β-globin gene cluster deletions
β-Globin gene mutations reduce or terminate the production of beta globin chains, of which approximately 10% are large deletions within the β-globin gene cluster. Because gene deletion leads to loss of heterozygosity at single nucleotide polymorphism (SNP), a novel method for detecting β-globin gene cluster deletions based on SNP heterozygosity analysis was established in this study. The location range of SNPs was selected according to the breakpoint of β-globin gene cluster deletions. SNPs were screened using bioinformatics analysis and population sequencing data. A novel method which enables genotyping of multiplex SNPs based on tetra-primer ARMS-PCR was designed and optimized. Forty clinical samples were tested in parallel by this method and MLPA to verify the performance of this method for detecting β-globin gene cluster deletion. Six informative SNPs were obtained, achieving heterozygote coverage of 93.3% in normal individuals. Genotyping of six SNPs were successfully integrated into two multiplex tetra-primer ARMS-PCR reactions. The sensitivity, specificity, positive predictive value and negative predictive value of the method for detecting β-globin gene cluster deletion were 100%, 96.30%, 92.86%, and 100%, respectively. This is a simple, cost-effective and novel method for detecting β-globin gene cluster deletions, which may be suitable for use in combination with MLPA for thalassemia molecular testing.
- 26 October 2020
- Published by Springer Nature in Scientific Reports
- Vol. 10 (1) , 1-9
Open AccessEstablishment and application of a novel method based on single nucleotide polymorphism analysis for detecting β-globin gene cluster deletions
β-Globin gene mutations reduce or terminate the production of beta globin chains, of which approximately 10% are large deletions within the β-globin gene cluster. Because gene deletion leads to loss of heterozygosity at single nucleotide polymorphism (SNP), a novel method for detecting β-globin gene cluster deletions based on SNP heterozygosity analysis was established in this study. The location range of SNPs was selected according to the breakpoint of β-globin gene cluster deletions. SNPs were screened using bioinformatics analysis and population sequencing data. A novel method which enables genotyping of multiplex SNPs based on tetra-primer ARMS-PCR was designed and optimized. Forty clinical samples were tested in parallel by this method and MLPA to verify the performance of this method for detecting β-globin gene cluster deletion. Six informative SNPs were obtained, achieving heterozygote coverage of 93.3% in normal individuals. Genotyping of six SNPs were successfully integrated into two multiplex tetra-primer ARMS-PCR reactions. The sensitivity, specificity, positive predictive value and negative predictive value of the method for detecting β-globin gene cluster deletion were 100%, 96.30%, 92.86%, and 100%, respectively. This is a simple, cost-effective and novel method for detecting β-globin gene cluster deletions, which may be suitable for use in combination with MLPA for thalassemia molecular testing.
- Open Access
- 1 January 2020
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 44 (2) , 234-244
Histone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases
Hu S, et al. Diabetes Metab J. 2020 Jan;44:e7. https://doi.org/10.4093/dmj.2019.0243
- 1 January 2020
- Published by Korean Diabetes Association in Diabetes & Metabolism Journal
- Vol. 44 (2) , 234-244
Open AccessHistone Deacetylase 9: Its Role in the Pathogenesis of Diabetes and Other Chronic Diseases
Hu S, et al. Diabetes Metab J. 2020 Jan;44:e7. https://doi.org/10.4093/dmj.2019.0243
- Open Access
- 11 September 2019
- Published by MDPI AG in Antioxidants
- Vol. 8 (9) , 390
Zeaxanthin: Metabolism, Properties, and Antioxidant Protection of Eyes, Heart, Liver, and Skin
Zeaxanthin, a non-provitamin A carotenoid that belongs to the xanthophyll family, has been less studied than its isomer lutein. However, zeaxanthin has also been shown to have a number of beneficial effects for human health due to its ability to quench free radicals, exert antioxidant effects, as well as decrease inflammation. It is the purpose of this review to discuss the metabolism of zeaxanthin, including digestion, absorption, transport, and uptake by tissues, as well as the dietary or other factors which affect zeaxanthin bioavailability. In addition, this review also focuses on specific effects of this carotenoid on eye, skin, liver, and cardiovascular health. Data derived from human interventions, animal models of research, and in vitro and cell studies are discussed in this review.
- 11 September 2019
- Published by MDPI AG in Antioxidants
- Vol. 8 (9) , 390
Open AccessZeaxanthin: Metabolism, Properties, and Antioxidant Protection of Eyes, Heart, Liver, and Skin
Zeaxanthin, a non-provitamin A carotenoid that belongs to the xanthophyll family, has been less studied than its isomer lutein. However, zeaxanthin has also been shown to have a number of beneficial effects for human health due to its ability to quench free radicals, exert antioxidant effects, as well as decrease inflammation. It is the purpose of this review to discuss the metabolism of zeaxanthin, including digestion, absorption, transport, and uptake by tissues, as well as the dietary or other factors which affect zeaxanthin bioavailability. In addition, this review also focuses on specific effects of this carotenoid on eye, skin, liver, and cardiovascular health. Data derived from human interventions, animal models of research, and in vitro and cell studies are discussed in this review.
- 1 September 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (9) , 2451-2463
Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis
- 1 September 2019
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1865 (9) , 2451-2463
Nicotinamide riboside, an NAD+ precursor, attenuates the development of liver fibrosis in a diet-induced mouse model of liver fibrosis
- Open Access
- 30 June 2019
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 24 (2) , 103-113
Health Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases with a prevalence of ~25% worldwide. NAFLD includes simple hepatic steatosis, non-alcoholic steatohepatitis, fibrosis, and cirrhosis, which can further progress to hepatocellular carcinoma. Therefore, effective strategies for the prevention of NAFLD are needed. The pathogenesis of NAFLD is complicated due to diverse injury insults, such as fat accumulation, oxidative stress, inflammation, lipotoxicity, and apoptosis, which may act synergistically. Studies have shown that carotenoids, a natural group of isoprenoid pigments, prevent the development of NAFLD by exerting antioxidant, lipid-lowering, anti-inflammatory, anti-fibrotic, and insulin-sensitizing properties. This review summarizes the protective action of carotenoids, with primary focuses on astaxanthin, lycopene, β-carotene, β-cryptoxanthin, lutein, fucoxanthin, and crocetin, against the development and progression of NAFLD.
- 30 June 2019
- Published by The Korean Society of Food Science and Nutrition in Preventive Nutrition and Food Science
- Vol. 24 (2) , 103-113
Open AccessHealth Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases with a prevalence of ~25% worldwide. NAFLD includes simple hepatic steatosis, non-alcoholic steatohepatitis, fibrosis, and cirrhosis, which can further progress to hepatocellular carcinoma. Therefore, effective strategies for the prevention of NAFLD are needed. The pathogenesis of NAFLD is complicated due to diverse injury insults, such as fat accumulation, oxidative stress, inflammation, lipotoxicity, and apoptosis, which may act synergistically. Studies have shown that carotenoids, a natural group of isoprenoid pigments, prevent the development of NAFLD by exerting antioxidant, lipid-lowering, anti-inflammatory, anti-fibrotic, and insulin-sensitizing properties. This review summarizes the protective action of carotenoids, with primary focuses on astaxanthin, lycopene, β-carotene, β-cryptoxanthin, lutein, fucoxanthin, and crocetin, against the development and progression of NAFLD.